viewCynata Therapeutics Ltd

Cynata Therapeutics meets with New York investors following good news from its stem cell candidate

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD).

Macdonald is in New York to present at the 20th Annual Rodman & Renshaw Global Investment Conference. Macdonald says Cynata's recent clinical data has "opened a lot of doors" to institutional investors, plus he says having a corporate partner in FUJIFILM (TYO:4901) helps to validate the technology.

Quick facts: Cynata Therapeutics Ltd

Price: 0.69 AUD

Market: ASX
Market Cap: $71.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...



Cynata Therapeutics’ market-disruptive regenerative medicines complete...

Killian Kelly, vice president product development at Cynata Therapeutics Ltd (ASX:CYP), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Cynata Therapeutics has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product...

on 6/9/18

2 min read